MZOR
Mazor Robotics Ltd.NASDAQ
1d
5d
1m
6m
1y
5y
10y
Advanced Chart
  • Tue, Nov. 8, 5:14 AM
    • Mazor Robotics (NASDAQ:MZOR): Q3 EPS of -$0.11 beats by $0.08.
    • Revenue of $7.6M (+53.2% Y/Y) misses by $0.09M.
    • Press Release
    | Tue, Nov. 8, 5:14 AM
  • Mon, Nov. 7, 5:30 PM
  • Mon, Oct. 10, 12:45 PM
    | Mon, Oct. 10, 12:45 PM | 1 Comment
  • Mon, Oct. 10, 11:01 AM
    | Mon, Oct. 10, 11:01 AM
  • Mon, Oct. 10, 9:16 AM
    | Mon, Oct. 10, 9:16 AM | 2 Comments
  • Mon, Oct. 10, 8:47 AM
    • Thinly traded micro cap Mazor Robotics (NASDAQ:MZOR) is up 8% premarket on modest volume in response to its announcement that it received 25 purchase orders for its systems in Q3, including three pre-launch orders for its new Mazor X guidance system and 15 orders from strategic partner Medtronic (NYSE:MDT).
    • At the end of Q3, Mazor's installed base of Renaissance systems was 131 globally, including 79 in the U.S.
    | Mon, Oct. 10, 8:47 AM
  • Fri, Oct. 7, 11:48 AM
    • Lexicon Pharmaceuticals (NASDAQ:LXRX) initiated with Buy rating and $26 (38% upside) price target by H.C. Wainwright.
    • Zynerba Pharmaceuticals (NASDAQ:ZYNE) initiated with Buy rating and $22 (54% upside) price target by H.C. Wainwright.
    • Mazor Robotics (NASDAQ:MZOR) initiated with Buy rating and $25 (10% upside) price target by B. Riley.
    • Lipocine (NASDAQ:LPCN) initiated with Buy rating and $25 (350% upside) price target by H.C. Wainwright.
    • TG Therapeutics (NASDAQ:TGTX) initiated with Buy rating and $28 (218% upside) price target by Brean Capital.
    • Immunomedics (NASDAQ:IMMU) initiated with Buy rating and $5.50 (113% upside) price target by Jefferies.
    • AmerisourceBergen (NYSE:ABC) initiated with Neutral rating by UBS.
    • ARIAD Pharmaceuticals (NASDAQ:ARIA) initiated with Buy rating and $22 (65% upside) price target by SunTrust Robinson Humphrey.
    • Amarin (NASDAQ:AMRN) initiated with Buy rating and $6 (92% upside) price target by Cantor Fitzgerald.
    • Corbus Pharmaceuticals (NASDAQ:CRBP) initiated with Buy rating and $17 (94% upside) price target by Cantor Fitzgerald.
    • Heron Therapeutics (NASDAQ:HRTX) initiated with Buy rating and $41 (142% upside) price target by Brean Capital.
    • Zogenix (NASDAQ:ZGNX) initiated with Outperform rating and $17 (64% upside) price target by Leerink Swann.
    • GW Pharmaceuticals (NASDAQ:GWPH) initiated with Outperform rating and $162 (23% upside) price target by Leerink Swann. Initiated with Buy rating and $189 (44% upside) price target by Goldman Sachs.
    • SAGE Therapeutics (NASDAQ:SAGE) initiated with Outperform rating and $68 (57% upside) price target by Leerink Swann.
    • Alexion Pharmaceuticals (NASDAQ:ALXN) initiated with Buy rating and $221 (79% upside) price target by Brean Capital.
    • Axsome Therapeutics (NASDAQ:AXSM) initiated with Buy rating and $20 (136% upside) price target by Brean Capital.
    • Recro Pharma (NASDAQ:REPH) initiated with Buy rating and $21 (156% upside) price target by Brean Capital.
    • SCYNEXIS (NASDAQ:SCYX) initiated with Buy rating and $16 (226% upside) price target by Brean Capital.
    • Sorrento Therapeutics (NASDAQ:SRNE) initiated with Buy rating and $15 (94% upside) price target by Roth Capital.
    • Global Blood Therapeutics (NASDAQ:GBT) initiated with Outperform rating and a $75 - 81 (322% upside from midpoint) target price range by Wells Fargo.
    • Alder Biopharmaceuticals (NASDAQ:ALDR) initiated with Buy rating and $45 (49% upside) price target by Brean Capital.
    | Fri, Oct. 7, 11:48 AM | 8 Comments
  • Mon, Aug. 15, 10:06 AM
    • Triggered by the unveiling of Mazor Robotics' (MZOR -0.3%) Mazor X Surgical Assistance Platform, Medtronic (MDT +0.4%) invests an additional $20M in the Israeli robotic surgery products developer, raising its stake to 7.27%. Medtronic made an initial investment of $11.9M in May when the companies inked a deal granting Medtronic exclusive global distribution rights to Mazor's future spine products and established Mazor as Medtronic's exclusive strategic partner for the development and commercialization of robotic spine systems and applications.
    • Mazor currently markets the Renaissance guidance system used in spine surgery.
    • Previously: Mazor Robotics inks deal with Medtronic; shares up 23% premarket (May 18)
    | Mon, Aug. 15, 10:06 AM | 1 Comment
  • Tue, Aug. 2, 4:51 AM
    • Mazor Robotics (NASDAQ:MZOR): Q2 EPS of -$0.09 beats by $0.02.
    • Revenue of $8.28M (+6.2% Y/Y) misses by $0.23M.
    • Press Release
    | Tue, Aug. 2, 4:51 AM
  • Mon, Aug. 1, 5:30 PM
  • Tue, Jul. 12, 9:53 AM
    • Mazor Robotics (MZOR) unveils its Mazor X, a new guidance system for spine surgeries. Commercial launch will commence at the North American Spine Society annual meeting in Boston in October.
    • Medtronic (MDT +0.2%) will co-promote Mazor X in the U.S. It has already placed an initial order for 15 devices. If all goes well, Medtronic will assume exclusive global distribution rights for Mazor's future spine products in 2018.
    • Previously: Mazor Robotics inks deal with Medtronic; shares up 23% premarket (May 18)
    | Tue, Jul. 12, 9:53 AM | 3 Comments
  • Wed, Jul. 6, 6:44 AM
    • Thinly traded micro cap Mazor Robotics (NASDAQ:MZOR) is up 4% premarket on light volume in response to its announcement that it booked orders for 11 Renaissance systems in Q2, including two with the brain module. Five of the orders came from international distributors: three in China, one in Italy and one in Australia.
    • The company ended the quarter with an installed base of 122 Renaissance systems, including 74 in the U.S. Q2 results will be released in August.
    • Renaissance is a guidance system that surgeons use in spine surgery.
    | Wed, Jul. 6, 6:44 AM
  • Tue, Jul. 5, 12:50 PM
    | Tue, Jul. 5, 12:50 PM
  • Fri, May 20, 7:32 AM
    • Arrowhead Pharmaceuticals (NASDAQ:ARWR) initiated with Buy rating and $12 (140% upside) price target by Chardan Capital.
    • Amicus Therapeutics (NASDAQ:FOLD) initiated with Buy rating and $10 (45% upside) price target by Bank of America.
    • Quorum Health (NYSE:QHC) initiated with Equal Weight rating and $12 (2% upside) price target by Morgan Stanley.
    • TESARO (NASDAQ:TSRO) initiated with Outperform rating and $56 (30% upside) price target by Credit Suisse.
    • Prothena (NASDAQ:PRTA) initiated with Overweight rating and $60 (47% upside) price target by Barclays.
    • Mazor Robotics (NASDAQ:MZOR) upgraded to Outperform from Market Perform by Wells Fargo. Price target raised to $15-17 (14% upside from midpoint) from $10-13.
    • Eli Lilly (NYSE:LLY) upgraded to Strong Buy with a price target of $88.67 (19% upside) by the Vetr Community.
    • Haemonetics (NYSE:HAE) upgraded to Neutral from Sell by Goldman Sachs. Price target raised to $29 (5% upside) from $25.
    • Nanosphere (NASDAQ:NSPH) downgraded to Neutral from Buy by Rodman & Renshaw. Price target lowered to $1.35 (2% upside) from $2.00.
    • Anacor Pharmaceuticals (NASDAQ:ANAC) downgraded to Neutral from Buy by Mizuho Securities. Price target set at $99.25 (0% upside).
    • Globus Medical (NYSE:GMED) downgraded to Sell from Neutral by Goldman Sachs. Price target lowered to $21 (10% downside risk) from $26.
    • EPIRUS Biopharmaceuticals (NASDAQ:EPRS) downgraded to Market Perform from Outperform by Leerink Swann. Price target lowered to $0.75 (27% upside).
    | Fri, May 20, 7:32 AM | 10 Comments
  • Wed, May 18, 12:46 PM
    | Wed, May 18, 12:46 PM | 2 Comments
  • Wed, May 18, 9:15 AM
    | Wed, May 18, 9:15 AM